NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia

Phase 3

Completed

Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Promyelocytic Leukemia (M3)
Childhood Acute Promyelocytic Leukemia (M3)
Untreated Adult Acute Myeloid Leukemia
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

Interventions: Drug: tretinoin
Drug: daunorubicin hydrochloride
Drug: cytarabine
Drug: arsenic trioxide
Drug: mercaptopurine
Drug: methotrexate

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 420

Registration Number: NCT00003934

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Phase 2

Completed

Conditions: Recurrent Melanoma
Stage IV Melanoma

Interventions: Biological: recombinant interleukin-12
Biological: recombinant interferon alfa
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00026143

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: alvocidib
Drug: irinotecan hydrochloride
Drug: fluorouracil
Drug: leucovorin calcium
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 77

Registration Number: NCT00042874

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Procedure: conventional surgery
Radiation: 3-dimensional conformal radiation therapy
Radiation: stereotactic radiosurgery
Drug: motexafin gadolinium
Procedure: magnetic resonance imaging
Procedure: spectroscopy

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00004262

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Recurrent Esophageal Cancer
Squamous Cell Carcinoma of the Esophagus
Stage III Esophageal Cancer
Stage IV Esophageal Cancer

Interventions: Drug: erlotinib hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT00045526

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

Phase 1

Completed

Conditions: Male Breast Cancer
Recurrent Breast Cancer
Recurrent Endometrial Carcinoma
Recurrent Gastric Cancer
Recurrent Non-small Cell Lung Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Small Cell Lung Cancer

Interventions: Biological: trastuzumab
Drug: paclitaxel
Biological: recombinant interleukin-12

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00028535

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Adult Acute Eosinophilic Leukemia
Adult Acute Erythroid Leukemia (M6)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Basophilic Leukemia
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)

Interventions: Drug: cytarabine
Biological: aldesleukin
Other: clinical observation
Drug: daunorubicin hydrochloride
Biological: filgrastim
Drug: etoposide
Other: pharmacological study
Drug: valspodar
Drug: busulfan
Procedure: autologous hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 720

Registration Number: NCT00006363

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Noncontiguous Stage II Marginal Zone Lymphoma
Noncontiguous Stage II Small Lymphocytic Lymphoma
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Recurrent Marginal Zone Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Splenic Marginal Zone Lymphoma

Interventions: Biological: apolizumab
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00017472

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: suramin
Drug: carboplatin
Drug: paclitaxel
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 82

Registration Number: NCT00006929

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic

Phase 3

Completed

Conditions: HER2-negative Breast Cancer
HER2-positive Breast Cancer
Recurrent Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: paclitaxel
Biological: trastuzumab
Procedure: quality-of-life assessment
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 580

Registration Number: NCT00003440

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Home Terms & Conditions Privacy Policy